company background image
GMAB

Genmab CPSE:GMAB Stock Report

Last Price

kr.2.66k

Market Cap

kr.173.5b

7D

6.8%

1Y

-4.5%

Updated

05 Oct, 2022

Data

Company Financials +
GMAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

GMAB Stock Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

Genmab Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Pricekr.2,660.00
52 Week Highkr.3,124.00
52 Week Lowkr.1,863.00
Beta0.62
1 Month Change-1.12%
3 Month Change8.62%
1 Year Change-4.49%
3 Year Change97.26%
5 Year Change87.32%
Change since IPO1,041.63%

Recent News & Updates

Aug 29
Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?

Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Shareholder Returns

GMABDK BiotechsDK Market
7D6.8%6.2%2.0%
1Y-4.5%-7.7%-9.0%

Return vs Industry: GMAB exceeded the Danish Biotechs industry which returned -7% over the past year.

Return vs Market: GMAB exceeded the Danish Market which returned -8.3% over the past year.

Price Volatility

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement4.5%
Biotechs Industry Average Movement7.9%
Market Average Movement5.6%
10% most volatile stocks in DK Market10.5%
10% least volatile stocks in DK Market3.1%

Stable Share Price: GMAB is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: GMAB's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19991,445Jan G.J. van Winkelhttps://www.genmab.com

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

Genmab Fundamentals Summary

How do Genmab's earnings and revenue compare to its market cap?
GMAB fundamental statistics
Market Capkr.173.51b
Earnings (TTM)kr.3.96b
Revenue (TTM)kr.10.21b

43.8x

P/E Ratio

17.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GMAB income statement (TTM)
Revenuekr.10.21b
Cost of Revenuekr.0
Gross Profitkr.10.21b
Other Expenseskr.6.25b
Earningskr.3.96b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 09, 2022

Earnings per share (EPS)60.74
Gross Margin100.00%
Net Profit Margin38.81%
Debt/Equity Ratio0%

How did GMAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is GMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GMAB?

Other financial metrics that can be useful for relative valuation.

GMAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.9x
Enterprise Value/EBITDA41x
PEG Ratio2x

Price to Earnings Ratio vs Peers

How does GMAB's PE Ratio compare to its peers?

GMAB PE Ratio vs Peers
The above table shows the PE ratio for GMAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average40.7x
A068270 Celltrion
42.2x21.4%₩23.6t
ALK B ALK-Abelló
87.9x34.0%kr.27.9b
INCY Incyte
16.4x28.6%US$15.5b
300122 Chongqing Zhifei Biological Products
16.4x15.8%CN¥138.3b
GMAB Genmab
43.8x21.9%kr.173.5b

Price-To-Earnings vs Peers: GMAB is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the peer average (40.7x).


Price to Earnings Ratio vs Industry

How does GMAB's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Earnings vs Industry: GMAB is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the European Biotechs industry average (34.3x)


Price to Earnings Ratio vs Fair Ratio

What is GMAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GMAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.8x
Fair PE Ratio34.4x

Price-To-Earnings vs Fair Ratio: GMAB is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the estimated Fair Price-To-Earnings Ratio (34.4x).


Share Price vs Fair Value

What is the Fair Price of GMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GMAB (DKK2660) is trading below our estimate of fair value (DKK7843.37)

Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


21.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMAB's forecast earnings growth (21.9% per year) is above the savings rate (0.1%).

Earnings vs Market: GMAB's earnings (21.9% per year) are forecast to grow faster than the Danish market (9.2% per year).

High Growth Earnings: GMAB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GMAB's revenue (18.3% per year) is forecast to grow faster than the Danish market (6.7% per year).

High Growth Revenue: GMAB's revenue (18.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GMAB's Return on Equity is forecast to be low in 3 years time (18.3%).


Discover growth companies

Past Performance

How has Genmab performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


25.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GMAB has a high level of non-cash earnings.

Growing Profit Margin: GMAB's current net profit margins (38.8%) are higher than last year (34.3%).


Past Earnings Growth Analysis

Earnings Trend: GMAB's earnings have grown significantly by 25.8% per year over the past 5 years.

Accelerating Growth: GMAB's earnings growth over the past year (57.7%) exceeds its 5-year average (25.8% per year).

Earnings vs Industry: GMAB earnings growth over the past year (57.7%) exceeded the Biotechs industry -16.7%.


Return on Equity

High ROE: GMAB's Return on Equity (16.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Genmab's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: GMAB's short term assets (DKK25.5B) exceed its short term liabilities (DKK1.9B).

Long Term Liabilities: GMAB's short term assets (DKK25.5B) exceed its long term liabilities (DKK1.1B).


Debt to Equity History and Analysis

Debt Level: GMAB is debt free.

Reducing Debt: GMAB has not had any debt for past 5 years.

Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Genmab current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Genmab Dividend Yield vs Market
How does Genmab dividend yield compare to the market?
SegmentDividend Yield
Company (Genmab)n/a
Market Bottom 25% (DK)1.8%
Market Top 25% (DK)6.7%
Industry Average (Biotechs)2.2%
Analyst forecast in 3 Years (Genmab)0%

Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GMAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Jan G.J. van Winkel (61 yo)

12.33yrs

Tenure

kr.38,100,000

Compensation

Dr. Jan G.J. van de Winkel, Ph D., served as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.Dr. Winkel is Director of LEO Pha...


CEO Compensation Analysis

Jan G.J. van Winkel's Compensation vs Genmab Earnings
How has Jan G.J. van Winkel's remuneration changed compared to Genmab's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

kr.4b

Mar 31 2022n/an/a

kr.2b

Dec 31 2021kr.38mkr.8m

kr.3b

Sep 30 2021n/an/a

kr.3b

Jun 30 2021n/an/a

kr.3b

Mar 31 2021n/an/a

kr.6b

Dec 31 2020kr.37mkr.7m

kr.5b

Sep 30 2020n/an/a

kr.6b

Jun 30 2020n/an/a

kr.6b

Mar 31 2020n/an/a

kr.2b

Dec 31 2019kr.35mkr.7m

kr.2b

Sep 30 2019n/an/a

kr.2b

Jun 30 2019n/an/a

kr.1b

Mar 31 2019n/an/a

kr.1b

Dec 31 2018kr.28mkr.7m

kr.1b

Sep 30 2018n/an/a

kr.1b

Jun 30 2018n/an/a

kr.1b

Mar 31 2018n/an/a

kr.1b

Dec 31 2017kr.27mkr.7m

kr.1b

Sep 30 2017n/an/a

kr.1b

Jun 30 2017n/an/a

kr.1b

Mar 31 2017n/an/a

kr.1b

Dec 31 2016kr.23mkr.6m

kr.1b

Sep 30 2016n/an/a

kr.735m

Jun 30 2016n/an/a

kr.686m

Mar 31 2016n/an/a

kr.535m

Dec 31 2015kr.20mkr.5m

kr.764m

Compensation vs Market: Jan G.J. van's total compensation ($USD5.05M) is above average for companies of similar size in the Danish market ($USD3.02M).

Compensation vs Earnings: Jan G.J. van's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: GMAB's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: GMAB's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of GMAB?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders651,8991.0%
General Public28,610,62143.9%
Institutions35,966,87955.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 43.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.15%
BlackRock, Inc.
5,318,358DKK14.1b-0.09%0.04%
5.54%
Wellington Management Group LLP
3,614,501DKK9.6b-0.02%0.22%
5.5%
Baillie Gifford & Co.
3,590,603DKK9.6b0.04%0.62%
5.22%
Artisan Partners Limited Partnership
3,403,444DKK9.1b-2.81%1.18%
3.39%
The Vanguard Group, Inc.
2,214,159DKK5.9b1.57%0.02%
2.58%
Capital Research and Management Company
1,683,501DKK4.5b-0.04%0.04%
2.05%
Norges Bank Investment Management
1,334,814DKK3.6b0%0.06%
1.33%
T. Rowe Price Group, Inc.
869,262DKK2.3b-0.49%0.03%
0.94%
Jan G.J. van Winkel
614,657DKK1.6b0%no data
0.91%
Macquarie Investment Management Business Trust
592,535DKK1.6b5.97%0.22%
0.9%
UBS Asset Management
585,159DKK1.6b-0.6%0.04%
0.78%
Candriam Luxembourg S.A.
508,493DKK1.4b-1.99%0.61%
0.68%
Amundi Asset Management
445,813DKK1.2b11.98%0.05%
0.67%
American Century Investment Management Inc
438,162DKK1.2b-0.2%0.11%
0.61%
J.P. Morgan Asset Management, Inc.
395,376DKK1.1b-2.21%0.02%
0.6%
Handelsbanken Asset Management
388,769DKK1.0b1.45%0.28%
0.57%
Federated Hermes, Inc.
372,376DKK990.5m-4.27%0.38%
0.55%
Geode Capital Management, LLC
357,469DKK950.9m-0.02%0.02%
0.51%
BNPP Asset Management Holding
329,476DKK876.4m-2.29%0.23%
0.5%
AllianceBernstein L.P.
323,672DKK861.0m-1.57%0.04%
0.37%
Pictet Asset Management Limited
240,922DKK640.9m0%0.07%
0.36%
Lazard Asset Management LLC
234,513DKK623.8m2.08%0.08%
0.36%
Polar Capital Holdings plc
231,618DKK616.1m-15.38%0.42%
0.35%
Deutsche Asset & Wealth Management
228,413DKK607.6m9.92%0.03%
0.34%
DNB Asset Management AS
219,490DKK583.8m-5.96%0.28%

Company Information

Genmab A/S's employee growth, exchange listings and data sources


Key Information

  • Name: Genmab A/S
  • Ticker: GMAB
  • Exchange: CPSE
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr.173.510b
  • Shares outstanding: 65.23m
  • Website: https://www.genmab.com

Number of Employees


Location

  • Genmab A/S
  • Kalvebod Brygge 43
  • Copenhagen
  • Capital Region of Denmark
  • 1560
  • Denmark


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNMS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2000
GMABCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKOct 2000
GE9DB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2000
GE9XTRA (XETRA Trading Platform)YesOrdinary SharesDEEUROct 2000
0MGBLSE (London Stock Exchange)YesOrdinary SharesGBDKKOct 2000
GMABCBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBDKKOct 2000
GMABWBAG (Wiener Boerse AG)YesOrdinary SharesATEUROct 2000
GMAB NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNOct 2000
GMABNasdaqGS (Nasdaq Global Select)SPON ADR EACH REP 0.1 ORD SHSUSUSDMay 2013
GE91BST (Boerse-Stuttgart)SPON ADR EACH REP 0.1 ORD SHSDEEURMay 2013

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/10/05 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.